PMID- 22023243
OWN - NLM
STAT- MEDLINE
DCOM- 20120820
LR  - 20211203
IS  - 1945-0257 (Electronic)
IS  - 1945-0257 (Linking)
VI  - 16
IP  - 4
DP  - 2012 Apr
TI  - Evaluation of genetic status of HER-2/neu and aneusomy 17 by fluorescence in situ 
      hybridization and comparison with immunohistochemistry assay from Indian breast 
      cancer patients.
PG  - 239-45
LID - 10.1089/gtmb.2011.0125 [doi]
AB  - AIMS: The HER-2/neu proto-oncogene is amplified in 15%-25% of breast cancers. In 
      the current study, we evaluated HER-2/neu status of 396 cases of breast cancer by 
      fluorescence in situ hybridization (FISH), and the results were correlated with 
      immunohistochemistry (IHC) for HER-2/neu protein expression. RESULTS: Overall, 
      HER-2/neu amplification was observed in 38.4% of cases. Concordance between IHC 
      and FISH was 90.4% considering only IHC score 0, 1 (negative), and 3 (positive). 
      However, only 37.3% of the IHC score 2 (equivocal) cases showed HER-2/neu gene 
      amplification. A majority of the discordant cases within the IHC negative (score 
      0 and 1) and IHC positive (score 3) were high-grade tumors. Polysomy 17 and 
      monosomy 17 was seen in 7.3% of the total cases of each. Furthermore, a majority 
      of FISH positive cases were noted in Intraductal Carcinoma grade III and cases 
      with regional lymph nodal metastasis. Polysomy 17 was seen in 7.9% of the FISH 
      positive cases and in 6.3% of the FISH negative cases. Monosomy 17, however was 
      more preponderant in FISH negative cases. CONCLUSION: We believe that the FISH 
      test should be considered as the gold standard in the estimation of the HER-2/neu 
      status due to its increased sensitivity and better appreciation of aneusomy 17.
FAU - Kokate, Prajakta
AU  - Kokate P
AD  - Cytogenetic Division, Super Religare Laboratories Ltd., Mumbai, India.
FAU - Sawaimoon, Satyakam
AU  - Sawaimoon S
FAU - Bhatia, Simi
AU  - Bhatia S
FAU - Mandava, Swarna
AU  - Mandava S
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
DEP - 20111024
PL  - United States
TA  - Genet Test Mol Biomarkers
JT  - Genetic testing and molecular biomarkers
JID - 101494210
RN  - 0 (MAS1 protein, human)
RN  - 0 (Proto-Oncogene Mas)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - *Aneuploidy
MH  - Breast Neoplasms/*genetics/metabolism/pathology
MH  - Carcinoma, Intraductal, Noninfiltrating/*genetics/metabolism/pathology
MH  - Chromosomes, Human, Pair 17/*genetics
MH  - Female
MH  - Genes, erbB-2
MH  - Humans
MH  - Immunohistochemistry/methods
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - India
MH  - Middle Aged
MH  - Proto-Oncogene Mas
MH  - Receptor, ErbB-2/*genetics/metabolism
EDAT- 2011/10/26 06:00
MHDA- 2012/08/21 06:00
CRDT- 2011/10/26 06:00
PHST- 2011/10/26 06:00 [entrez]
PHST- 2011/10/26 06:00 [pubmed]
PHST- 2012/08/21 06:00 [medline]
AID - 10.1089/gtmb.2011.0125 [doi]
PST - ppublish
SO  - Genet Test Mol Biomarkers. 2012 Apr;16(4):239-45. doi: 10.1089/gtmb.2011.0125. 
      Epub 2011 Oct 24.